Gain Therapeutics Inc.

NASDAQ: GANX · Real-Time Price · USD
1.73
0.19 (12.34%)
At close: Aug 15, 2025, 3:59 PM
1.76
1.73%
After-hours: Aug 15, 2025, 07:49 PM EDT

Gain Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 82.24K n/a n/a n/a 64.8K n/a n/a 55.18K 140.11K n/a 95.1K 45.01K 36.34K 27.34K 89.17K 5.27K
Cost of Revenue
n/a 20.66K 21.31K 21.64K 20.59K 20.53K 23.59K 20.51K n/a n/a 18.11K n/a 18.24K 8.21K n/a n/a n/a n/a
Gross Profit
n/a -20.66K -21.31K -21.64K -20.59K -20.53K -23.59K -20.51K -20.24K n/a 122K -19.61K 76.86K 36.8K -1.44M -2.45M -1.7M -1.42M
Operating Income
-5.09M -4.37M -3.33M -4.46M -8.18M -4.38M -4.41M -4.89M -7.73M -5.23M -4.56M -4.75M -5.18M -3.29M -3.21M -4.64M -3.51M -2.47M
Interest Income
42.57K 40.41K 51.86K 105.41K 84.53K 115.3K 106.27K 106K 129.93K n/a n/a n/a 59.9K n/a n/a n/a n/a n/a
Pretax Income
-5.67M -4.43M -3.26M -4.47M -8.14M -3.99M -4.71M -4.7M -7.66M -5.12M -4.6M -4.55M -5.08M -3.27M -3.23M -4.66M -3.55M -2.45M
Net Income
-5.81M -4.53M -3.77M -4.49M -8.14M -4.01M -4.72M -4.72M -7.69M -5.14M -4.67M -4.56M -5.09M -3.27M -3.22M -4.66M -3.56M -2.45M
Selling & General & Admin
2.33M 2.11M 2.11M 1.84M 3.75M 1.86M 2.02M 2.52M 3.74M 2.49M 2.29M 2.79M 2.69M 1.78M 1.78M 2.19M 1.81M 1.05M
Research & Development
2.76M 2.26M 1.21M 2.62M 4.44M 2.5M 2.37M 2.37M 3.99M 2.79M 2.27M 1.96M 2.58M 1.56M 1.47M 2.48M 1.79M 1.42M
Other Expenses
n/a n/a -11.31K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 18.93K -11.37K -7.56K n/a
Operating Expenses
5.09M 4.37M 3.31M 4.46M 8.18M 4.36M 4.38M 4.89M 7.73M 5.28M 4.56M 4.75M 5.27M 3.33M 3.25M 4.66M 3.6M 2.47M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.65K n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a -12.53K -14.77K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
5.09M 4.37M 3.33M 4.46M 8.18M 4.38M 4.41M 4.89M 7.73M 5.28M 4.56M 4.75M 5.27M 3.33M 3.25M 4.66M 3.6M 2.47M
Income Tax Expense
141.21K 100.51K 504.74K 10.99K 1.21K 19.87K 14.5K 21.46K 26.59K 16.73K 78.11K 4.05K 9.15K 1.68K -8.24K 5.11K 3.66K 3.48K
Shares Outstanding (Basic)
30.34M 28.69M 27.13M 26.53M 19.22M 17.98M 16.21M 12.7M 12.39M 11.94M 11.88M 11.88M 11.83M 11.88M 10.17M 11.88M 11.88M 11.6M
Shares Outstanding (Diluted)
30.34M 28.69M 27.13M 26.53M 19.22M 17.98M 16.21M 12.7M 12.39M 11.94M 11.88M 11.88M 11.88M 11.88M 10.17M 11.88M 11.88M 11.6M
EPS (Basic)
-0.19 -0.16 -0.14 -0.17 -0.42 -0.22 -0.29 -0.37 -0.62 -0.43 -0.39 -0.38 -0.43 -0.28 -0.32 -0.39 -0.3 -0.21
EPS (Diluted)
-0.19 -0.16 -0.14 -0.17 -0.42 -0.22 -0.29 -0.37 -0.62 -0.43 -0.39 -0.38 -0.43 -0.28 -0.32 -0.39 -0.3 -0.21
EBITDA
-5.09M -4.37M -3.31M -4.44M -8.16M -4.37M -4.4M -4.89M -7.72M -5.21M -4.54M -4.75M -5.18M -3.28M -3.21M -4.6M -3.51M -2.46M
EBIT
-5.67M -4.37M -3.33M -4.46M -8.18M -4.38M -4.41M -4.89M -7.73M -5.23M -4.56M -4.75M -5.18M -3.29M -3.21M -4.64M -3.51M -2.47M
Depreciation & Amortization
n/a 20.66K 21.31K 21.64K 20.59K 20.53K 23.59K 20.51K 20.24K 19.24K 18.11K 19.61K 18.24K 8.21K 5.79K 54.27K 2.16K 3.4K